Ibrutinib

CAS 936563-96-1 19 current records 2 historicalSmall Molecule

Who holds supplier records for Ibrutinib? 19 organisations hold a current record for Ibrutinib: an active US FDA Type II Drug Master File. A further 2 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (10), China (5), Taiwan (1), Netherlands (1) and 1 other country (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Ibrutinib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/ibrutinib

Reading the evidence

  • 19 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 10 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Ibrutinib expires 14 Jun 2039. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (19)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Ibrutinib. Country is the organisation's recorded country, not necessarily the manufacturing site.

India10China5Taiwan1Netherlands1Israel1Country not recorded for 1
  • MSN Laboratories Private Limited
    Active DMF 34768, 33357, 30557 +1 · latest filing Sept 2020
    India Company GMP cert on record
  • Dr. Reddy's Laboratories Ltd.
    Active DMF 31792, 37311 · latest filing Nov 2022
    India Company GMP cert on record
  • Wisdom Pharmaceutical Co., Ltd
    Active DMF 31917, 38919 · latest filing Sept 2023
    China
  • AARTI PHARMALABS LIMITED
    Active DMF 43912 · latest filing Apr 2026
    India
  • Alembic Pharmaceuticals Limited
    Active DMF 32880 · latest filing Jul 2018
    India Company GMP cert on record
  • BEIJING HOPE PHARMACEUTICAL CO LTD
    Active DMF 37000 · latest filing Mar 2022
  • CDYMAX (INDIA) PHARMA PRIVATE LIMITED
    Active DMF 40228 · latest filing Dec 2024
    India Company GMP cert on record
  • ESTEVE HUAYI PHARMACEUTICAL CO LTD
    Active DMF 31679 · latest filing May 2017
    China
  • Hetero Labs Limited
    Active DMF 31689 · latest filing Aug 2017
    India Company GMP cert on record
  • Natco Pharma
    Active DMF 32937 · latest filing Aug 2018
    India Company GMP cert on record
  • SCINOPHARM TAIWAN LTD
    Active DMF 30925 · latest filing Dec 2016
    Taiwan
  • SHILPA PHARMA LIFESCIENCES LTD
    Active DMF 32122 · latest filing Oct 2017
    India
  • Sichuan Kelun Pharmaceutical Co., Ltd.
    Active DMF 42690 · latest filing Sept 2025
    China
  • Sun Pharmaceutical Industries Limited
    Active DMF 31547 · latest filing Sept 2017
    India Company GMP cert on record
  • SYNTHIMED LABS PRIVATE LIMITED
    Active DMF 41389 · latest filing Jul 2025
    India Company GMP cert on record
  • TAPI NL BV
    Active DMF 31631 · latest filing Jun 2017
    Netherlands
  • WAVELENGTH ENTERPRISES LTD
    Active DMF 30746 · latest filing Aug 2016
    Israel Company GMP cert on record
  • Zhejiang Ausun Pharmaceutical Co., Ltd.
    Active DMF 44199 · latest filing May 2026
    China Company GMP cert on record
  • Zhejiang Huayi Pharmaceutical Co., Ltd.
    Active DMF 40794 · latest filing Nov 2024
    China
Need Ibrutinib sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (2)

Organisations whose Type II DMFs for Ibrutinib are no longer active. These show a past filing, not current supply.

Show all 2 historical records

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (7 listed products contain Ibrutinib). The latest listed patent expires 14 Jun 2039. The latest listed exclusivity runs to 24 Feb 2030. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Ibrutinib is an orally administered small molecule that acts as a Bruton's tyrosine kinase (BTK) inhibitor, used primarily for the treatment of certain cancers of the blood and lymphatic system, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By inhibiting BTK, ibrutinib disrupts B-cell receptor signaling pathways essential for the survival and proliferation of malignant B cells.

Chemical identity

IUPAC name
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
Canonical SMILES
C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
InChIKey
XYFPWWZEPKGCCK-GOSISDBHSA-N
Synonyms
Imbruvica API, cra-032765, imbruvica, pc-32765, pci 32765, pci-32765, pci-32765-00

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Kinase Inhibitor
Mechanism of action
Protein Kinase Inhibitors

Therapeutic areas

HematologyOncologyImmunology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Ibrutinib?

19 organisations hold an active US FDA Type II Drug Master File or a CEP for Ibrutinib: MSN Laboratories Private Limited (India), Dr. Reddy's Laboratories Ltd. (India), Wisdom Pharmaceutical Co., Ltd (China), AARTI PHARMALABS LIMITED (India), Alembic Pharmaceuticals Limited (India), BEIJING HOPE PHARMACEUTICAL CO LTD, CDYMAX (INDIA) PHARMA PRIVATE LIMITED (India) and ESTEVE HUAYI PHARMACEUTICAL CO LTD (China), and 11 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Ibrutinib Drug Master Files are active?

MSN Laboratories Private Limited (DMF 34768, 33357), Dr. Reddy's Laboratories Ltd. (DMF 31792, 37311), Wisdom Pharmaceutical Co., Ltd (DMF 31917, 38919), AARTI PHARMALABS LIMITED (DMF 43912), Alembic Pharmaceuticals Limited (DMF 32880), BEIJING HOPE PHARMACEUTICAL CO LTD (DMF 37000), CDYMAX (INDIA) PHARMA PRIVATE LIMITED (DMF 40228) and ESTEVE HUAYI PHARMACEUTICAL CO LTD (DMF 31679) and 11 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Ibrutinib records mean?

2 organisations have only inactive Type II DMFs for Ibrutinib. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Ibrutinib?

Yes. The latest patent listed for an approved US product containing Ibrutinib expires 14 Jun 2039, across 7 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Ibrutinib supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Ibrutinib?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.